To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

Phase 2

Completed

• Conditions: Schizophrenia; Schizoaffective Disorder

• Registration Number: NCT00141479
• Lead Sponsor: Solvay Pharmaceuticals

Brief Summary

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-05
• Study First Submitted: 2005-08-30
• Study First Submitted QC: 2005-08-30
• Study First Posted: 2005-09-01
• Status Verified: 2006-05
• Primary Completion: 2006-11
• Study Completion: 2006-11
• Last Update Submitted: 2015-01-15
• Last Update Posted: 2015-01-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Diagnosis of Schizophrenia or Schizoaffective disorder
• 18-55 years

Exclusion Criteria

• Subjects who are acutely psychotic
• Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia
• Subjects at significant risk of suicide
• Subjects with a seizure disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

Site 1; 🇺🇸 Wichita, Kansas, United States